ri-1

RI-1 (RAD51 inhibitor 1) is a RAD51 inhibitor (IC50: 5-30 μM).

1,2,3-Tri-10(Z)-undecenoyl glycerol is a triglyceride composed of 10-undecenoic acid esterified at the sn-1, sn-2, and sn-3 positions.

DDRI-18 is a novel small molecule inhibitor that regulates the DNA damage response with sensitizing and anticancer activities, inhibits non-homologous end-joining (NHEJ) DNA repair and enhances the cytotoxicity of anticancer DNA damage compounds.

TRi-1 is irreversible inhibitor of cytosolic thioredoxin reductase 1 (TXNRD1), with an IC50 of 12 nM. TRi-1 has little mitochondrial toxicity for anticancer therapy

ARI-1 is a receptor tyrosine kinase-like orphan receptor 1 (ROR1) inhibitor that binds to ROR1's extracellular Frizzled domain, effectively inhibiting aberrant ROR1 expression linked to non-small cell lung cancer (NSCLC) and EGFR-TKI-induced drug resistance. It modulates PI3K/AKT/mTOR signaling pathways in a ROR1-dependent manner and demonstrates potent inhibition of NSCLC cell proliferation and migration, exhibiting antitumor activity in vivo [1].

1,2,3-Tri-13(E)-docosenoyl glycerol, a triacylglycerol featuring 13(E)-docosenoic acid at the \(sn-1\), \(sn-2\), and \(sn-3\) positions, transiently elevates heart triglyceride levels in weanling rats when administered as 15% of a calcium-deficient diet, with levels returning to baseline after 28 days.

1,2,3-Tri-11(Z)-eicosenoyl glycerol, a triacylglycerol with 11(Z)-eicosenoic acid at the sn-1,sn-2, and sn-3 positions, serves as an internal standard for quantifying triacylglycerols in seed and olive oils.

AHR Inhibitor I-103 is an aryl hydrocarbon receptor (AHR) inhibitor with anticancer activity used in the study of breast cancer and acute myeloid leukemia.

Zevaquenabant ((S)-MRI-1867), a dual cannabinoid CB1 receptor and inducible NOS (iNOS) antagonist, is orally bioavailable and peripherally restricted. It effectively mitigates obesity-induced chronic kidney disease (CKD).

IST-622 is a unique topoisomerase inhibitor, showing significant growth-inhibitory effects against large-cell lung cancer (Lu-116) and gastric adenocarcinoma (St-4).

Kri 1314 is a cyclohexyl-norstatine-containing dipeptide renin inhibitor which has potential for the treatment of hypertension.

Monlunabant ((S)-MRI-1891), a solid dispersion compound, functions as an inhibitor of the cannabinoid CB1 receptor [1].

F-CRI1, a potent STING agonist with a dissociation constant (K d) of 40.62 nM, is an 18F-labeled radioactive probe employed for visualizing STING in the tumor microenvironment [1].

(R)-Monlunabant ((R)-MRI-1891) is a CB1 receptor antagonist used in obesity and metabolic disease research [1].

Prosupride (GRI 1665) is a neuroleptic agent that selectively blocks dopaminergic receptors.

(R)-Zevaquenabant ((R)-MRI-1867) is the enantiomer of Zevaquenabant. Zevaquenabant ((S)-MRI-1867) is a peripherally restricted, orally bioavailable dual antagonist of the cannabinoid CB1 receptor and inducible nitric oxide synthase (iNOS). It is beneficial in improving chronic kidney disease (CKD) caused by obesity.

RI(dl)-2 TFA is a potent and selective inhibitor of RAD51-mediated D-loop formation, with an IC50 of 11.1 μM, and inhibits homologous recombination (HR) activity in human cells with an IC50 of 3.0 μM [1].

5'-O-DMT-Ri can be used in the synthesis of oligoribonucleotides[1]. [1]. Kadokura M. Synthesis of 4-thiouridine, 6-thioinosine, and 6-thioguanosine 3',5'-O-bisphosphates as donor molecules for RNA ligation and their application to the synthesis of photoactivatable TMG-capped U1 snRNA fragments. J Org Chem. 2000 Aug 25;65(17):5104-13.

Pegsunercept (PEG sTNF-RI), a pegylated monoclonal antibody, selectively binds to TNFA, incorporating a polyethylene glycol (pegol) moiety [1].

RI-OR2 is a retro-inverso peptide that acts as an amyloid-β (Aβ) oligomerization inhibitor. It binds to fixed β-Amyloid (1-42) monomers and fibrils, with an apparent Kd of 9-12 μM, and also serves as an inhibitor of Aβ(1-42) fibril extension.